Get Cash Back and $0 Commissions
+ The Power of TradeStation
PRNewswire 23-Apr-2019 6:00 AM
ST. LOUIS, April 23, 2019 /PRNewswire/ -- Centene Corporation (NYSE:CNC) announced today its financial results for the first quarter ended March 31, 2019, reporting diluted earnings per share (EPS) of $1.24, and Adjusted Diluted EPS of $1.39.
In summary, the 2019 first quarter results were as follows:
Total revenues (in millions) |
$ |
18,444 |
||
Health benefits ratio |
85.7 |
% |
||
SG&A expense ratio |
9.6 |
% |
||
GAAP diluted EPS |
$ |
1.24 |
||
Adjusted Diluted EPS (1) |
$ |
1.39 |
||
Total cash flow provided by operations (in millions) |
$ |
1,316 |
||
(1) A full reconciliation of Adjusted Diluted EPS is shown on page six of this release. |
Michael F. Neidorff, Centene's Chairman and Chief Executive Officer, stated, "Solid first quarter results and increased 2019 guidance are indicative of the sustainability of our profitable growth trajectory. We continue to focus on the fundamentals of the business that will drive long-term shareholder value, irrespective of headline volatility."
First Quarter Highlights
Other Events
Membership
The following table sets forth our membership by line of business:
March 31, |
|||||
2019 |
2018 |
||||
Medicaid: |
|||||
TANF, CHIP & Foster Care |
7,491,100 |
5,776,600 |
|||
ABD & LTSS |
1,036,200 |
866,000 |
|||
Behavioral Health |
56,000 |
454,500 |
|||
Total Medicaid |
8,583,300 |
7,097,100 |
|||
Commercial |
2,472,700 |
2,161,200 |
|||
Medicare (1) |
393,900 |
343,400 |
|||
Correctional |
153,200 |
157,300 |
|||
Total at-risk membership |
11,603,100 |
9,759,000 |
|||
TRICARE eligibles |
2,855,800 |
2,851,500 |
|||
Non-risk membership |
211,900 |
218,900 |
|||
Total |
14,670,800 |
12,829,400 |
|||
(1) Membership includes Medicare Advantage, Medicare Supplement, Special Needs Plans, and Medicare-Medicaid Plans (MMP). |
The following table sets forth additional membership statistics, which are included in the membership information above:
March 31, |
|||||
2019 |
2018 |
||||
Dual-eligible (2) |
625,600 |
438,200 |
|||
Health Insurance Marketplace |
1,968,700 |
1,603,800 |
|||
Medicaid Expansion |
1,312,100 |
1,057,400 |
|||
(2) Membership includes dual-eligible ABD & LTSS and dual-eligible Medicare membership in the table above. |
Revenues
The following table sets forth supplemental revenue information for the three months ended March 31, ($ in millions):
2019 |
2018 |
% Change |
|||||||||
Medicaid |
$ |
12,608 |
$ |
8,205 |
54 |
% |
|||||
Commercial |
3,645 |
3,063 |
19 |
% |
|||||||
Medicare (1) |
1,382 |
1,162 |
19 |
% |
|||||||
Other |
809 |
764 |
6 |
% |
|||||||
Total Revenues |
$ |
18,444 |
$ |
13,194 |
40 |
% |
|||||
(1) Medicare includes Medicare Advantage, Medicare Supplement, Special Needs Plans, and MMP. |
Statement of Operations: Three Months Ended March 31, 2019
Balance Sheet
At March 31, 2019, the Company had cash, investments and restricted deposits of $14.8 billion, including $507 million held by unregulated entities. Medical claims liabilities totaled $7.4 billion. The Company's days in claims payable was 48 days, which is consistent with year end. Total debt was $6.8 billion, which includes $357 million of borrowings on our $1.5 billion revolving credit facility at quarter end. The debt to capitalization ratio was 36.5% at March 31, 2019, excluding $135 million of non-recourse debt.
Outlook
The Company's annual guidance for 2019 has been updated for the following significant items:
The Company's updated annual guidance for 2019 is as follows:
Full Year 2019 |
|||||||||
Low |
High |
||||||||
Total revenues (in billions) |
$ |
72.8 |
$ |
73.6 |
|||||
GAAP diluted EPS |
$ |
3.67 |
$ |
3.84 |
|||||
Adjusted Diluted EPS (1) |
$ |
4.24 |
$ |
4.44 |
|||||
HBR |
86.5 |
% |
87.0 |
% |
|||||
SG&A expense ratio |
9.4 |
% |
9.9 |
% |
|||||
Adjusted SG&A expense ratio (2) |
9.3 |
% |
9.8 |
% |
|||||
Effective tax rate |
24.5 |
% |
26.5 |
% |
|||||
Diluted shares outstanding (in millions) |
421.0 |
422.0 |
|||||||
(1) |
Adjusted Diluted EPS excludes amortization of acquired intangible assets of $0.46 to $0.47 per diluted share and acquisition related expenses of $0.11 to $0.13 per diluted share. |
(2) |
Adjusted SG&A expense ratio excludes acquisition related expenses of $62 million to $74 million. |
Conference Call
As previously announced, the Company will host a conference call Tuesday, April 23, 2019, at approximately 8:30 AM (Eastern Time) to review the financial results for the first quarter ended March 31, 2019. Michael Neidorff and Jeffrey Schwaneke will host the conference call.
Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 1795523 to expedite caller registration; or via a live, audio webcast on the Company's website at www.centene.com, under the Investors section.
A webcast replay will be available for on-demand listening shortly after the completion of the call for the next twelve months or until 11:59 PM (Eastern Time) on Tuesday, April 21, 2020, at the aforementioned URL. In addition, a digital audio playback will be available until 9:00 AM (Eastern Time) on Tuesday, April 30, 2019, by dialing 1-877-344-7529 in the U.S. and Canada, or +1-412-317-0088 from abroad, and entering access code 10129281.
Non-GAAP Financial Presentation
The Company is providing certain non-GAAP financial measures in this release as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. The Company uses the presented non-GAAP financial measures internally to allow management to focus on period-to-period changes in the Company's core business operations. Therefore, the Company believes that this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The presentation of this additional non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.
Specifically, the Company believes the presentation of non-GAAP financial information that excludes amortization of acquired intangible assets and acquisition related expenses allows investors to develop a more meaningful understanding of the Company's performance over time. The tables below provide reconciliations of non-GAAP items ($ in millions, except per share data):
Three Months Ended |
|||||||
2019 |
2018 |
||||||
GAAP net earnings attributable to Centene |
$ |
522 |
$ |
340 |
|||
Amortization of acquired intangible assets |
65 |
39 |
|||||
Acquisition related expenses |
18 |
21 |
|||||
Income tax effects of adjustments (1) |
(20) |
(14) |
|||||
Adjusted net earnings |
$ |
585 |
$ |
386 |
(1) |
The income tax effects of adjustments are based on the effective income tax rates applicable to adjusted (non-GAAP) results. |
Three Months Ended |
Annual |
||||||||
March 31, |
Guidance |
||||||||
2019 |
2018 |
December 31, |
|||||||
2019 |
|||||||||
GAAP diluted EPS attributable to Centene |
$ |
1.24 |
$ |
0.96 |
$3.67 - $3.84 |
||||
Amortization of acquired intangible assets (1) |
0.12 |
0.09 |
$0.46 - $0.47 |
||||||
Acquisition related expenses (2) |
0.03 |
0.04 |
$0.11 - $0.13 |
||||||
Adjusted Diluted EPS |
$ |
1.39 |
$ |
1.09 |
$4.24 - $4.44 |
(1) |
The amortization of acquired intangible assets per diluted share presented above is net of an income tax benefit of $0.04 and $0.02 for the three months ended March 31, 2019 and 2018, respectively, and an estimated $0.14 for the year ended December 31, 2019. |
(2) |
The acquisition related expenses per diluted share presented above are net of an income tax benefit of $0.01 and $0.02 for the three months ended March 31, 2019 and 2018, respectively, and an estimated $0.04 for the year ended December 31, 2019. |
Three Months Ended |
|||||||
2019 |
2018 |
||||||
GAAP SG&A expenses |
$ |
1,609 |
$ |
1,316 |
|||
Acquisition related expenses |
17 |
21 |
|||||
Adjusted SG&A expenses |
$ |
1,592 |
$ |
1,295 |
About Centene Corporation
Centene Corporation, a Fortune 100 company, is a diversified, multi-national healthcare enterprise that provides a portfolio of services to government sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Many receive benefits provided under Medicaid, including the State Children's Health Insurance Program (CHIP), as well as Aged, Blind or Disabled (ABD), Foster Care and Long-Term Services and Supports (LTSS), in addition to other state-sponsored programs, Medicare (including the Medicare prescription drug benefit commonly known as "Part D"), dual eligible programs and programs with the U.S. Department of Defense. Centene also provides healthcare services to groups and individuals delivered through commercial health plans. Centene operates local health plans and offers a range of health insurance solutions. It also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health management, care management software, correctional healthcare services, dental benefits management, commercial programs, home-based primary care services, life and health management, vision benefits management, pharmacy benefits management, specialty pharmacy and telehealth services.
Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, http://www.centene.com/investors.
Forward-Looking Statements
All statements, other than statements of current or historical fact, contained in this press release are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "seek," "target," "goal," "may," "will," "would," "could," "should," "can," "continue" and other similar words or expressions (and the negative thereof). Centene (the Company, our, or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our future operating or financial performance, market opportunity, growth strategy, competition, expected activities in completed and future acquisitions, including statements about the impact of our proposed acquisition (the WellCare Transaction) of WellCare Health Plans, Inc. (WellCare), our recent acquisition (the Fidelis Care Acquisition) of substantially all the assets of New York State Catholic Health Plan, Inc., d/b/a Fidelis Care New York ( Fidelis Care), investments and the adequacy of our available cash resources. These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions. All forward-looking statements included in this press release are based on information available to us on the date hereof. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this press release, whether as a result of new information, future events or otherwise, after the date hereof. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including but not limited to: the risk that regulatory or other approvals required for the WellCare Transaction may be delayed or not obtained or are obtained subject to conditions that are not anticipated that could require the exertion of management's time and our resources or otherwise have an adverse effect on us; the risk that our stockholders do not approve the issuance of shares of Centene common stock in the WellCare Transaction; the risk that WellCare's stockholders do not adopt the merger agreement (the Merger Agreement); the possibility that certain conditions to the consummation of the WellCare Transaction will not be satisfied or completed on a timely basis and, accordingly, the WellCare Transaction may not be consummated on a timely basis or at all; uncertainty as to the expected financial performance of the combined company following completion of the WellCare Transaction; the possibility that the expected synergies and value creation from the WellCare Transaction will not be realized, or will not be realized within the expected time period; the exertion of management's time and the Company's resources, and other expenses incurred and business changes required, in connection with any regulatory, governmental or third party consents or approvals for the WellCare Transaction; the risk that unexpected costs will be incurred in connection with the completion and/or integration of the WellCare Transaction or that the integration of WellCare will be more difficult or time consuming than expected; the risk that potential litigation in connection with the WellCare Transaction may affect the timing of the WellCare Transaction, cause it not to close at all, or result in significant costs of defense, indemnification and liability; unexpected costs, charges or expenses resulting from the WellCare Transaction; the possibility that competing offers will be made to acquire WellCare; the inability to retain key personnel; disruption from the announcement, pendency and/or completion of the WellCare Transaction, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; the risk that, following the WellCare Transaction, the combined company may not be able to effectively manage its expanded operations; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves; competition; membership and revenue declines or unexpected trends; changes in healthcare practices, new technologies, and advances in medicine; increased healthcare costs; changes in economic, political or market conditions; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act, collectively referred to as the Affordable Care Act (ACA) and any regulations enacted thereunder that may result from changing political conditions or judicial actions, including the ultimate outcome of the District Court decision in "Texas v. United States of America" regarding the constitutionality of the ACA; rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting our government businesses; our ability to adequately price products on federally facilitated and state-based Health Insurance Marketplaces; tax matters; disasters or major epidemics; the outcome of legal and regulatory proceedings; changes in expected contract start dates; provider, state, federal and other contract changes and timing of regulatory approval of contracts; the expiration, suspension, or termination of our contracts with federal or state governments (including but not limited to Medicaid, Medicare, TRICARE or other customers); the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; challenges to our contract awards; cyber-attacks or other privacy or data security incidents; the possibility that the expected synergies and value creation from acquired businesses, including, without limitation, the Fidelis Care Acquisition, will not be realized, or will not be realized within the expected time period; the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for acquisitions, including the Fidelis Care Acquisition; disruption caused by significant completed and pending acquisitions, including, among others, the Fidelis Care Acquisition, making it more difficult to maintain business and operational relationships; the risk that unexpected costs will be incurred in connection with the completion and/or integration of acquisition transactions, including among others, the Fidelis Care Acquisition; changes in expected closing dates, estimated purchase price and accretion for acquisitions; the risk that acquired businesses, including Fidelis Care, will not be integrated successfully; the risk that, following the Fidelis Care Acquisition, we may not be able to effectively manage our expanded operations; restrictions and limitations in connection with our indebtedness; our ability to maintain the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; availability of debt and equity financing, on terms that are favorable to us; inflation; foreign currency fluctuations; and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission. This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition and results of operations, in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future medical and selling, general and administrative costs.
[Tables Follow]
CENTENE CORPORATION AND SUBSIDIARIES |
|||||||
CONSOLIDATED BALANCE SHEETS |
|||||||
(In millions, except shares in thousands and per share data in dollars) |
|||||||
March 31, 2019 |
December 31, 2018 |
||||||
(Unaudited) |
|||||||
ASSETS |
|||||||
Current assets: |
|||||||
Cash and cash equivalents |
$ |
6,345 |
$ |
5,342 |
|||
Premium and trade receivables |
5,819 |
5,150 |
|||||
Short-term investments |
697 |
722 |
|||||
Other current assets |
755 |
784 |
|||||
Total current assets |
13,616 |
11,998 |
|||||
Long-term investments |
7,186 |
6,861 |
|||||
Restricted deposits |
582 |
555 |
|||||
Property, software and equipment, net |
1,800 |
1,706 |
|||||
Goodwill |
6,981 |
7,015 |
|||||
Intangible assets, net |
2,208 |
2,239 |
|||||
Other long-term assets |
1,196 |
527 |
|||||
Total assets |
$ |
33,569 |
$ |
30,901 |
|||
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY |
|||||||
Current liabilities: |
|||||||
Medical claims liability |
$ |
7,381 |
$ |
6,831 |
|||
Accounts payable and accrued expenses |
4,641 |
4,051 |
|||||
Return of premium payable |
718 |
666 |
|||||
Unearned revenue |
363 |
385 |
|||||
Current portion of long-term debt |
40 |
38 |
|||||
Total current liabilities |
13,143 |
11,971 |
|||||
Long-term debt |
6,775 |
6,648 |
|||||
Other long-term liabilities |
2,007 |
1,259 |
|||||
Total liabilities |
21,925 |
19,878 |
|||||
Commitments and contingencies |
|||||||
Redeemable noncontrolling interests |
10 |
10 |
|||||
Stockholders' equity: |
|||||||
Preferred stock, $0.001 par value; authorized 10,000 shares; no shares issued or outstanding at March 31, 2019 and December 31, 2018 |
— |
— |
|||||
Common stock, $0.001 par value; authorized 800,000 shares; 419,058 issued and 413,305 outstanding at March 31, 2019, and 417,695 issued and 412,478 outstanding at December 31, 2018 |
— |
— |
|||||
Additional paid-in capital |
7,491 |
7,449 |
|||||
Accumulated other comprehensive earnings (loss) |
38 |
(56) |
|||||
Retained earnings |
4,185 |
3,663 |
|||||
Treasury stock, at cost (5,753 and 5,217 shares, respectively) |
(174) |
(139) |
|||||
Total Centene stockholders' equity |
11,540 |
10,917 |
|||||
Noncontrolling interest |
94 |
96 |
|||||
Total stockholders' equity |
11,634 |
11,013 |
|||||
Total liabilities, redeemable noncontrolling interests and stockholders' equity |
$ |
33,569 |
$ |
30,901 |
CENTENE CORPORATION AND SUBSIDIARIES |
|||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||
(In millions, except shares in thousands and per share data in dollars) |
|||||||
(Unaudited) |
|||||||
Three Months Ended March 31, |
|||||||
2019 |
2018 |
||||||
Revenues: |
|||||||
Premium |
$ |
16,203 |
$ |
11,903 |
|||
Service |
635 |
653 |
|||||
Premium and service revenues |
16,838 |
12,556 |
|||||
Premium tax and health insurer fee |
1,606 |
638 |
|||||
Total revenues |
18,444 |
13,194 |
|||||
Expenses: |
|||||||
Medical costs |
13,882 |
10,039 |
|||||
Cost of services |
544 |
543 |
|||||
Selling, general and administrative expenses |
1,609 |
1,316 |
|||||
Amortization of acquired intangible assets |
65 |
39 |
|||||
Premium tax expense |
1,659 |
546 |
|||||
Health insurer fee expense |
— |
171 |
|||||
Total operating expenses |
17,759 |
12,654 |
|||||
Earnings from operations |
685 |
540 |
|||||
Other income (expense): |
|||||||
Investment and other income |
99 |
41 |
|||||
Interest expense |
(99) |
(68) |
|||||
Earnings from operations, before income tax expense |
685 |
513 |
|||||
Income tax expense |
166 |
175 |
|||||
Net earnings |
519 |
338 |
|||||
Loss attributable to noncontrolling interests |
3 |
2 |
|||||
Net earnings attributable to Centene Corporation |
$ |
522 |
$ |
340 |
|||
Net earnings per common share attributable to Centene Corporation: |
|||||||
Basic earnings per common share |
$ |
1.26 |
$ |
0.98 |
|||
Diluted earnings per common share |
$ |
1.24 |
$ |
0.96 |
|||
Weighted average number of common shares outstanding: |
|||||||
Basic |
412,924 |
347,843 |
|||||
Diluted |
419,752 |
355,380 |
|||||
CENTENE CORPORATION AND SUBSIDIARIES |
|||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||
(In millions) |
|||||||
(Unaudited) |
|||||||
Three Months Ended March 31, |
|||||||
2019 |
2018 |
||||||
Cash flows from operating activities: |
|||||||
Net earnings |
$ |
519 |
$ |
338 |
|||
Adjustments to reconcile net earnings to net cash provided by operating activities |
|||||||
Depreciation and amortization |
155 |
104 |
|||||
Stock compensation expense |
38 |
33 |
|||||
Deferred income taxes |
23 |
30 |
|||||
Changes in assets and liabilities |
|||||||
Premium and trade receivables |
(662) |
(176) |
|||||
Other assets |
20 |
51 |
|||||
Medical claims liabilities |
548 |
485 |
|||||
Unearned revenue |
(22) |
317 |
|||||
Accounts payable and accrued expenses |
357 |
157 |
|||||
Other long-term liabilities |
347 |
477 |
|||||
Other operating activities, net |
(7) |
30 |
|||||
Net cash provided by operating activities |
1,316 |
1,846 |
|||||
Cash flows from investing activities: |
|||||||
Capital expenditures |
(176) |
(218) |
|||||
Purchases of investments |
(580) |
(765) |
|||||
Sales and maturities of investments |
383 |
445 |
|||||
Acquisitions, net of cash acquired |
— |
(226) |
|||||
Net cash used in investing activities |
(373) |
(764) |
|||||
Cash flows from financing activities: |
|||||||
Proceeds from long-term debt |
1,018 |
2,015 |
|||||
Payments of long-term debt |
(927) |
(1,491) |
|||||
Common stock repurchases |
(35) |
(9) |
|||||
Other financing activities, net |
2 |
(2) |
|||||
Net cash provided by financing activities |
58 |
513 |
|||||
Net increase in cash, cash equivalents and restricted cash and cash equivalents |
1,001 |
1,595 |
|||||
Cash, cash equivalents, and restricted cash and cash equivalents, beginning of period |
5,350 |
4,089 |
|||||
Cash, cash equivalents, and restricted cash and cash equivalents, end of period |
$ |
6,351 |
$ |
5,684 |
|||
Supplemental disclosures of cash flow information: |
|||||||
Interest paid |
$ |
87 |
$ |
73 |
|||
Income taxes paid |
$ |
6 |
$ |
1 |
|||
Equity issued in connection with acquisitions |
$ |
— |
$ |
324 |
|||
The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the Consolidated Balance Sheets to the totals above: |
|||||||
March 31, |
|||||||
2019 |
2018 |
||||||
Cash and cash equivalents |
$ |
6,345 |
$ |
5,668 |
|||
Restricted cash and cash equivalents, included in restricted deposits |
6 |
16 |
|||||
Total cash, cash equivalents, and restricted cash and cash equivalents |
$ |
6,351 |
$ |
5,684 |
CENTENE CORPORATION |
|||||||||||||||||||
SUPPLEMENTAL FINANCIAL DATA |
|||||||||||||||||||
Q1 |
Q4 |
Q3 |
Q2 |
Q1 |
|||||||||||||||
2019 |
2018 |
2018 |
2018 |
2018 |
|||||||||||||||
MANAGED CARE MEMBERSHIP BY LINE OF BUSINESS |
|||||||||||||||||||
Medicaid: |
|||||||||||||||||||
TANF, CHIP & Foster Care |
7,491,100 |
7,356,200 |
7,260,500 |
5,852,000 |
5,776,600 |
||||||||||||||
ABD & LTSS |
1,036,200 |
1,002,100 |
964,200 |
874,200 |
866,000 |
||||||||||||||
Behavioral Health |
56,000 |
36,500 |
455,900 |
454,600 |
454,500 |
||||||||||||||
Total Medicaid |
8,583,300 |
8,394,800 |
8,680,600 |
7,180,800 |
7,097,100 |
||||||||||||||
Commercial |
2,472,700 |
1,978,000 |
2,062,500 |
2,051,700 |
2,161,200 |
||||||||||||||
Medicare (1) |
393,900 |
416,900 |
417,400 |
343,800 |
343,400 |
||||||||||||||
Correctional |
153,200 |
151,300 |
150,900 |
157,900 |
157,300 |
||||||||||||||
Total at-risk membership |
11,603,100 |
10,941,000 |
11,311,400 |
9,734,200 |
9,759,000 |
||||||||||||||
TRICARE eligibles |
2,855,800 |
2,858,900 |
2,858,900 |
2,851,500 |
2,851,500 |
||||||||||||||
Non-risk membership |
211,900 |
219,700 |
219,000 |
218,100 |
218,900 |
||||||||||||||
Total |
14,670,800 |
14,019,600 |
14,389,300 |
12,803,800 |
12,829,400 |
||||||||||||||
(1) Membership includes Medicare Advantage, Medicare Supplement, Special Needs Plans, and MMP. |
|||||||||||||||||||
NUMBER OF EMPLOYEES |
48,100 |
47,300 |
45,400 |
41,200 |
34,800 |
||||||||||||||
DAYS IN CLAIMS PAYABLE (2) |
48 |
48 |
51 |
44 |
43 |
||||||||||||||
(2) Days in claims payable is a calculation of medical claims liabilities at the end of the period divided by average claims expense per calendar day for such period. |
|||||||||||||||||||
CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions) |
|||||||||||||||||||
Regulated |
$ |
14,303 |
$ |
13,002 |
$ |
13,782 |
$ |
11,455 |
$ |
11,398 |
|||||||||
Unregulated |
507 |
478 |
481 |
3,543 |
452 |
||||||||||||||
Total |
$ |
14,810 |
$ |
13,480 |
$ |
14,263 |
$ |
14,998 |
$ |
11,850 |
|||||||||
DEBT TO CAPITALIZATION |
36.9 |
% |
37.8 |
% |
37.3 |
% |
37.0 |
% |
40.6 |
% |
|||||||||
DEBT TO CAPITALIZATION EXCLUDING NON-RECOURSE DEBT (3) |
36.5 |
% |
37.4 |
% |
36.9 |
% |
36.7 |
% |
40.3 |
% |
|||||||||
(3) The non-recourse debt represents the Company's mortgage note payable ($57 million at March 31, 2019) and construction loan payable ($78 million at March 31, 2019). |
|||||||||||||||||||
Debt to capitalization is calculated as follows: total debt divided by (total debt + total equity). |
OPERATING RATIOS
Three Months Ended March 31, |
|||||
2019 |
2018 |
||||
HBR |
85.7 |
% |
84.3 |
% |
|
SG&A expense ratio |
9.6 |
% |
10.5 |
% |
|
Adjusted SG&A expense ratio |
9.5 |
% |
10.3 |
% |
MEDICAL CLAIMS LIABILITY
The changes in medical claims liability are summarized as follows (in millions):
Balance, March 31, 2018 |
$ |
4,771 |
||
Less: reinsurance recoverable |
13 |
|||
Balance, March 31, 2018, net |
4,758 |
|||
Acquisitions and purchase accounting adjustments |
1,210 |
|||
Less: acquired reinsurance recoverable |
8 |
|||
Incurred related to: |
||||
Current period |
50,370 |
|||
Prior period (1) |
(470) |
|||
Total incurred |
49,900 |
|||
Paid related to: |
||||
Current period |
44,516 |
|||
Prior period |
3,983 |
|||
Total paid |
48,499 |
|||
Balance, March 31, 2019, net |
7,361 |
|||
Plus: reinsurance recoverable |
20 |
|||
Balance, March 31, 2019 |
$ |
7,381 |
||
(1) Incurred related to prior period does not include development on the acquired Fidelis Care medical claims liability as we closed that acquisition on July 1, 2018. Our Form 10-Q presents a rollforward for the three months ended March 31, 2019, which includes the development on Fidelis Care reserves, subsequent to the acquisition. |
Centene's claims reserving process utilizes a consistent actuarial methodology to estimate Centene's ultimate liability. Any reduction in the "Incurred related to: Prior period" amount may be offset as Centene actuarially determines "Incurred related to: Current period." As such, only in the absence of a consistent reserving methodology would favorable development of prior period claims liability estimates reduce medical costs. Centene believes it has consistently applied its claims reserving methodology. Additionally, approximately $46 million was recorded as a decrease to premium revenues resulting from development within "Incurred related to: Prior period" due to minimum HBR and other return of premium programs.
The amount of the "Incurred related to: Prior period" above represents favorable development and includes the effects of reserving under moderately adverse conditions, new markets where we use a conservative approach in setting reserves during the initial periods of operations, receipts from other third party payors related to coordination of benefits and lower medical utilization and cost trends for dates of service March 31, 2018, and prior.
View original content:http://www.prnewswire.com/news-releases/centene-corporation-reports-2019-first-quarter-results-and-increases-2019-guidance-300836048.html
SOURCE Centene Corporation